Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients

Phase 4

Completed

• Conditions: Adverse Reaction to Other Drugs and Medicines
• Interventions: Drug: cabergoline treatment

• Registration Number: NCT01957839
• Lead Sponsor: Istanbul Bakirkoy Maternity and Children Diseases Hospital

Brief Summary

the investigators examined the hypothesis that hyperprolactinemia may alter uterin, endometrial and intraovarian blood flow and may contribute to increased infertility by another way.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-03
• Primary Completion: 2011-08
• Study Completion: 2011-09
• Study First Submitted: 2013-09-10
• Status Verified: 2013-10
• Study First Submitted QC: 2013-10-07
• Last Update Submitted: 2013-10-07
• Study First Posted: 2013-10-08
• Last Update Posted: 2013-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 48

Inclusion Criteria

• Women who had blood prolactin level higher than 25ng/dl

Exclusion Criteria

• Pregnancy
• Use of drugs effecting vasculature such as hormonal therapy, oral contraceptives, antihypertensives
• Diseases like pelvic inflammatory disease and systemic hypertension
• Women with clinically overt or treated cardiovascular disease
• Concurrent illness other than hyperprolactinemia

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
posttreatment group	cabergoline treatment	doppler evaluatıon in normoprolactinemia women who given cabergoline treatment

Primary Outcome Measures

Name	Time	Method
th effect of prolactin vascular flow and resistance	the effect of prolactin in vascular resistance at 2 weeks after treatment

Trial Locations

Locations (1)

Sisli Etfal Teaching Hosital; 🇹🇷 Sisli, Turkey